Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome.
Am J Kidney Dis
; 70(5): 725-728, 2017 Nov.
Article
en En
| MEDLINE
| ID: mdl-28739329
Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Compuestos Organometálicos
/
Desequilibrio Hidroelectrolítico
/
Octreótido
/
Tumores Neuroendocrinos
/
Síndrome de Gitelman
/
Neoplasias del Íleon
Idioma:
En
Revista:
Am J Kidney Dis
Año:
2017
Tipo del documento:
Article
País de afiliación:
Italia